Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for sexual intercourse, serving as an early biomarker of endothelial dysfunction, metabolic disease, and cardiovascular risk. In cPNI perspective, ED reflects systemic inflammatory and metabolic dysfunction beyond isolated genital pathology.
Erection requires coordinated vascular, neurological, and hormonal function: parasympathetic activation triggers NO release from endothelial cells → cGMP production → smooth muscle relaxation → arterial dilation and venous compression. ED occurs when: (1) endothelial dysfunction reduces NO production (inflammation, oxidative stress, insulin resistance), (2) chronic RAAS activation causes vasoconstriction, (3) testosterone deficiency reduces libido and NO synthase expression, (4) sympathetic dominance prevents parasympathetic erectile signaling, (5) chronic inflammation impairs vascular function.
ED is a sentinel event indicating systemic endothelial dysfunction, often preceding cardiovascular events by 3-5 years. In cPNI practice, ED prompts investigation of metabolic syndrome, chronic inflammation, stress axes dysfunction, and hormonal imbalances. Treatment requires systemic metabolic optimization, not just phosphodiesterase inhibitors.
- Affects 50% of men aged 40-70 to varying degrees
- ED precedes cardiovascular events by average 3-5 years (shared vascular pathology)
- Penile arteries 1-2mm diameter show atherosclerosis earlier than coronary arteries (3-4mm)
- 80% of ED cases have vascular/metabolic causes (not psychological)
- Chronic stress/cortisol suppresses testosterone and promotes sympathetic dominance
- Metabolic syndrome increases ED risk 2-3 fold
- Low testosterone (<300 ng/dL) present in 30-40% of men with ED
- PDE5 inhibitors (Viagra) treat symptoms but not underlying pathology
- Endothelial dysfunction — primary pathophysiology involving impaired NO production
- Nitric Oxide — essential for smooth muscle relaxation and erection
- Metabolic syndrome — major risk factor through vascular and hormonal mechanisms
- Insulin resistance — impairs endothelial NO synthase and vascular function
- Testosterone — deficiency reduces libido and NO production capacity
- Chronic stress — suppresses testosterone and maintains sympathetic dominance
- Cortisol — chronic elevation suppresses gonadal axis
- Inflammation — chronic low-grade inflammation impairs endothelial function
- Atherosclerosis — vascular pathology affects penile arteries early
- Diabetes — 3x increased ED risk through vascular and nerve damage
- Hypertension — shares vascular pathology and RAAS overactivation
- RAAS — chronic activation causes vasoconstriction and endothelial damage
- ACE — ACE inhibitors may improve ED by reducing vasoconstriction
- Parasympathetic nervous system — must be active for erectile signaling (blocked by stress)
- Sympathetic dominance — prevents parasympathetic erectile mechanisms
- Obesity — increases ED risk through inflammation and hormonal changes
- Aromatase — elevated in obesity converts testosterone to estrogen
- Cardiovascular disease — ED is early warning sign of systemic vascular disease
- Oxidative Stress — impairs NO bioavailability through ROS
- L-Arginine — substrate for NO synthesis, may improve mild ED